FDA is keenly interested in these technologies because they could potentially provide flexibility for drug manufacturers to enable rapid and localized response to changing demand and increase timely access to quality drugs for U.S. patients.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/rFSOQib
No comments:
Post a Comment